Cambrex announced that it is expanding its mid-scale and large-scale API manufacturing capacity in Charles City, Iowa. The $50+ million investment is designed to meet the continually growing demand for small molecule drug substance development and manufacturing. It will be the sixth major investment that the company has made at the site in the past eight years to support customers in mid-scale, large-scale and highly potent small molecule API manufacturing. The expansion, which will be operational in early 2022, will add 3 large-scale manufacturing work centers and 1 mid-scale work center to the facility in Iowa, increasing the site's capacity by 30%. When completed, the Charles City site will employ more than 400 people. company's Charles City facility is located on a 45-acre site, and as part of the company's Drug Substance business unit, manufactures a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.